Osivax is a clinical stage biotechnology company, developing a pipeline of vaccines based on its proprietary technology: oligoDOM®. Founded in 2017 as a spin-off of IMAXIO, Osivax has now more than 20 employee based in Lyon and Liège.
Osivax is developing a pipeline of vaccines and immunotherapies based on its proprietary technology, oligoDOM®, which is designed to induce powerful CD8 T-cell responses. Osivax’ flagship program is a universal flu vaccine candidate covering both current and future infections. Osivax is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infection, as well as HPV and Malaria.
email@example.com – +33 4 37 65 55 03